Since Treg cells in the TME are a barrier to anti-tumor immune mechanisms and T cell priming, reducing the function of Tregs by potentiating anti-CTLA-4 mediators may be an essential strategy for the development of next-generation anti-CTLA-4 immunotherapy [209]. This evidence concerns the gene CTLA4 and neoplasm.